HER2-positive Metastatic Breast Cancer in Kazakhstan

N/ANot Yet RecruitingNCT07593196

AstraZeneca240 enrolled

Overview

Planned study population consists of approximately 240 adult patients with HER2-positive mBC receiving anti-HER2 therapy in 12 oncological centers (in each center it is expected to recruit about 20 patients) in different regions in order to provide representative study sample. Patients will be included consecutively from the least recent diagnosis (within defined time period). Planned retrospective follow-up period for 1 patient is a period starting from the date of mBC diagnosis until end study or until patient's death, whichever occurs first. End of study will be at least 12 months after the latest date of mBC diagnosis to ensure all patients have the opportunity to contribute at least 12 months of data.

Study Type

OBSERVATIONAL

Enrollment

240

Conditions

Metastatic Breast Cancer

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with HER2-positive mBC who are receiving or have started any anti-HER2 therapy (except for trastuzumab deruxtecan) at the time of inclusion * The diagnosis of mBC was established between the 1st January 2022 to 31st December 2023 * Patients with the availability of at least 24 months of follow-up data (from the date of mBC diagnosis) in the medical records at the participating site, unless patient died/moved or refused the therapy within the first 24 months of diagnosis * Age ≥18 years at the time of inclusion Exclusion Criteria: * Presence of other malignancies within the period from mBC diagnosis until the timepoint of data collection * Patients received trastuzumab deruxtecan * The participation in any interventional trial within period since diagnosis until the end of study

'Regional Cancer Centre' Uralsk

Oral, Kazakhstan, Kazakhstan

Medical Centre of the Marat Ospanov West Kazakhstan Medical University, Aktobe

Aktobe, Kazakhstan

'Kazakh Research Institute of Oncology and Radiology (KAZNIOR)'

Almaty, Kazakhstan

Almaty Cancer Centre

Almaty, Kazakhstan

'Multidisciplinary Medical Centre' of the Astana City Administration

Astana, Kazakhstan

National Cancer Research Centre, Astana

Astana, Kazakhstan

'Karaganda General Hospital No. 3' of the Karaganda Region Health Department

Karaganda, Kazakhstan

'General Regional Hospital' of the municipal state institution 'Health Department of the Akimat of North Kazakhstan Region' Petropavlovsk

Petropavl, Kazakhstan

'Centre for Nuclear Medicine and Oncology' Abai Regional Health Authority Semey

Semey, Kazakhstan

'Shymkent City General Hospital with Oncology Centre' under the Shymkent City Health Department

Shymkent, Kazakhstan

...and 2 more locations

Outcomes

Primary Outcomes

(1) To assess median PFS and PFS rate in patients with HER2-positive mBC receiving anti-HER2 therapy (except for trastuzumab deruxtecan) in routine practice in Kazakhstan

Time frame: up to 2 years

Secondary Outcomes

To describe the clinical and demographic characteristics of patients with HER2-positive mBC receiving anti-HER2 therapy (except for trastuzumab deruxtecan) in routine practice in Kazakhstan

Time frame: up to 2 years

(2) To describe the diagnostic algorithms and therapeutic tactics in patients with HER2-positive mBC in routine practice in Kazakhstan

Time frame: up to 2 years

(3) To describe the treatment approach in patients with HER2-positive mBC receiving anti-HER2 therapy (except for trastuzumab deruxtecan) in routine practice in Kazakhstan

Time frame: up to 2 years

(4) To assess the efficacy of anticancer treatment in patients with HER2-positive mBC receiving anti-HER2 therapy (except for trastuzumab deruxtecan) in routine practice in Kazakhstan

Time frame: up to 2 years

(5) To describe the reasons for anticancer therapy discontinuation in patients with HER2-positive mBC receiving anti-HER2 therapy (except for trastuzumab deruxtecan) in routine practice in Kazakhstan

Time frame: up to 2 years

(6) To assess the number of therapy lines of anticancer treatment in patients with HER2-positive mBC receiving anti-HER2 therapy (except for trastuzumab deruxtecan) in routine practice in Kazakhstan

Time frame: up to 2 years

HER2-positive Metastatic Breast Cancer in Kazakhstan

Overview

Conditions

Eligibility

Locations (12)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts